Asia-Pacific Breast Cancer Market Is Expected to Grow at a CAGR of 11.9% and Reach USD 4.75 Billion in 2024, Growing from USD 2.16 Billion in 2017
Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages of the disease, the survival rate rapidly decreases. HER2-positive breast cancer is an aggressive disease, and historically has had a worse overall survival (OS) than HER2-negative disease, which is considered less aggressive.
View full press release